夜色资源站www国产在线资源,国产偷窥熟妇高潮呻吟,潮湿的心动漫在线观看免费未删减,欧美日韩国产成人精品

當前位置:考試網  > 試卷庫  > 學歷類  > 自考  > 自考專業(公共關系)  > 公共關系策劃  >  某科技公司預購進一臺大型電子設備,半年來一直與 A 公司接洽,但雙方就價格問題遲遲未能達成一致。在最后一次談判中,該科技公司公關營銷代表認為, A 公司設備技術性能在國內并不處于領先地位,而且在交貨日期上,科技公司也可以延展期限。 A 公司談判代表認真考慮了科技公司代表的意見后,終于提出合理的價格,僵持半年的問題終于圓滿解決。 該科技公司的談判代表采取了什么公關技巧?這一技巧主要有哪些辦法?
試題預覽

某科技公司預購進一臺大型電子設備,半年來一直與 A 公司接洽,但雙方就價格問題遲遲未能達成一致。在最后一次談判中,該科技公司公關營銷代表認為, A 公司設備技術性能在國內并不處于領先地位,而且在交貨日期上,科技公司也可以延展期限。 A 公司談判代表認真考慮了科技公司代表的意見后,終于提出合理的價格,僵持半年的問題終于圓滿解決。

該科技公司的談判代表采取了什么公關技巧?這一技巧主要有哪些辦法?

查看答案
收藏
糾錯
正確答案:

該科技公司的談判代表采取了談判活動的公關技巧——追求雙贏。

這一技巧主要有以下方法:

(1)貨比三家

談判最重要的、最基礎的工作,就是了解信息,知己知彼,從而對己方談判的目標、報價、讓步及其策略都做到心中有數、胸有成竹。“貨比三家”,便通俗地表明了對談判關鍵信息了解掌握的重要性。

(2)追求雙贏

因為談判的目的是為了雙方進行愉快的、互惠互利的合作,且增進了解,建立友誼。如此,談判追求的便是“雙贏”,即雙方均得到滿足。

(3)緩兵之計

在談判中,雙方在交鋒中難免會遇到矛盾一時無法解決,這時最忌諱的就是意氣用事,過于針鋒相對,以至傷了和氣卻依然解決不了問題。這種時候,最好的選擇就是運用“緩兵之計”,在緩和氣氛后雙方再試圖進行靠攏。

(4)梯度讓步

幾乎所有的談判實踐均表明,平等的談判幾乎沒有不互相妥協、讓步的。如此,讓步就是談判中必不可少的正常手段。

答案解析:

暫無解析

你可能感興趣的試題

人為危機事件是指由與組織具有直接關系的人的行為所造成的()。

古人說:時移則勢異,勢異則情變,情變則法不同,講的是公關策劃的()

簡述公關策劃的趨勢

對人腦信息進行檢索的主要方式是()

對媒介傳播速度的分析,首先要考察媒介的()。

熱門試題 更多>
試題分類: 初級(口語)
練習次數:0次
試題分類: 口語
練習次數:0次
試題分類: 計算機四級
練習次數:0次
1.The failure of a high-profile cholesterol drug has thrown a spotlight on the complicated machinery that regulates cholesterol levels.But many researchers remain confident that drugs to boost levels of 'good' cholesterol are still one of the most promising means to combat spiralling heart disease. 2.Drug company Pfizer announced on 2 December that it was cancelling all clinical trials of torcetrapib,a drug designed to raise heart-protective high-density lipoproteins (HDLs).In a trial of 15000 patients,a safety board found that more people died or suffered cardiovascular problems after taking the drug plus a cholesterol-lowering statin than those in a control group who took the statin alone. 3.The news came as a kick in the teeth to many cardiologists because earlier tests in animals and people suggested it would lower rates of cardiovascular disease."There have been no red flags to my knowledge," says John Chapman,a specialist in lipoproteins and atherosclerosis at the National Institute for Health and Medical Research (INSERM) in Paris who has also studied torcetrapib."This cancellation came as a complete shock." 4.Torcetrapib is one of the most advanced of a new breed of drugs designed to raise levels of HDLs,which ferry cholesterol out of artery-clogging plaques to the liver for removal from the body.Specifically,torcetrapib blocks a protein called cholesterol ester transfer protein (CETP),which normally transfers the cholesterol from high-density lipoproteins to low density,plaque-promoting ones.Statins,in contrast,mainly work by lowering the 'bad' low-density lipoproteins. Under pressure 5.Researchers are now trying to work out why and how the drug backfired,something that will not become clear until the clinical details are released by Pfizer.One hint lies in evidence from earlier trials that it slightly raises blood pressure in some patients.It was thought that this mild problem would be offset by the heart benefits of the drug.But it is possible that it actually proved fatal in some patients who already suffered high blood pressure.If blood pressure is the explanation,it would actually be good news for drug developers because it suggests that the problems are specific to this compound.Other prototype drugs that are being developed to block CETP work in a slightly different way and might not suffer the same downfall. 6.But it is also possible that the whole idea of blocking CETP is flawed,says Moti Kashyap,who directs atherosclerosis research at the VA Medical Center in Long Beach,California.When HDLs excrete cholesterol in the liver,they actually rely on LDLs for part of this process.So inhibiting CETP,which prevents the transfer of cholesterol from HDL to LDL,might actually cause an abnormal and irreversible accumulation of cholesterol in the body."You're blocking a physiologic mechanism to eliminate cholesterol and effectively constipating the pathway," says Kashyap.Going up 7.Most researchers remain confident that elevating high density lipoproteins levels by one means or another is one of the best routes for helping heart disease patients.But HDLs are complex and not entirely understood.One approved drug,called niacin,is known to both raise HDL and reduce cardiovascular risk but also causes an unpleasant sensation of heat and tingling.Researchers are exploring whether they can bypass this side effect and whether niacin can lower disease risk more than statins alone.Scientists are also working on several other means to bump up high-density lipoproteins by,for example,introducing synthetic HDLs."The only thing we know is dead in the water is torcetrapib,not the whole idea of raising HDL," says Michael Miller,director of preventive cardiology at the University of Maryland Medical Center,Baltimore. Questions 7-13 Match torcetrapib,HDLs,statin and CETP with their functions (Questions 8-13)..Write the correct letter A,B,C or D in boxes 8-13 on your answer sheet.NB You may use any letter more than once. 7.It has been administered to over 10,000 subjects in a clinical trial. 8.It could help rid human body of cholesterol. 9.Researchers are yet to find more about it. 10.It was used to reduce the level of cholesterol. 11.According to Kashyap,it might lead to unwanted result if it's blocked. 12.It produced contradictory results in different trials. 13.It could inhibit LDLs.List of choices A.TorcetrapicB.HDLSC.StatinD.CETP
試題分類: 閱讀
練習次數:3次
試題分類: 初級(口語)
練習次數:0次
掃一掃,手機做題